LivaNova Director Sells 1,650 Shares for $131,500
Director Francesco Bianchi sold 1,650 ordinary shares of LivaNova (NASDAQ:LIVN) on Aug. 31, 2026, according to a recent SEC Form 4 filing . Transaction value based on SEC Form 4 weighted average sale price ($79.72); post-transaction value based on Aug. 31, 2026, market close ($79.81). LivaNova is a specialized medical technology company with a $4.3 billion market capitalization, employing 3,300 professionals across global operations headquartered in Gloucester. The company has demonstrated strong financial performance with TTM revenue of $1.5 billion and net income of $188.6 million, reflecting robust demand for its therapeutic device platforms in cardiac and neuromodulation markets. LivaNova maintains a competitive position through proprietary device technologies, established clinical relationships with leading surgeons and specialists, and a diversified product portfolio addressing critical therapeutic needs in cardiopulmonary and neurological treatment. Continue reading